Reflect Scientific, Inc. (RSCF)
USD 0.04
(1.27%)
USD 0.04
(1.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -405.78 Thousand USD | -377.34% |
| 2022 | 146.31 Thousand USD | -85.31% |
| 2021 | 996.22 Thousand USD | 37.72% |
| 2020 | 723.34 Thousand USD | 479.01% |
| 2019 | -190.85 Thousand USD | 22.38% |
| 2018 | -245.87 Thousand USD | 38.87% |
| 2017 | -402.18 Thousand USD | -63.3% |
| 2016 | -210.56 Thousand USD | 42.89% |
| 2015 | -431.22 Thousand USD | 36.42% |
| 2014 | -677.25 Thousand USD | -6.65% |
| 2013 | -847.57 Thousand USD | -410.04% |
| 2012 | 804.38 Thousand USD | 53.46% |
| 2011 | -321.46 Thousand USD | -205.1% |
| 2010 | 254.88 Thousand USD | 113.28% |
| 2009 | -2.46 Million USD | -263.22% |
| 2008 | 1.17 Million USD | 126.93% |
| 2007 | -4.33 Million USD | -445.37% |
| 2006 | -993.67 Thousand USD | -1193.59% |
| 2005 | 67.62 Thousand USD | -42.75% |
| 2004 | 127.89 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 116.34 Thousand USD | 910.97% |
| 2024 Q1 | -22.87 Thousand USD | 92.79% |
| 2023 Q3 | 95.83 Thousand USD | 157.71% |
| 2023 FY | - USD | -377.34% |
| 2023 Q4 | -202.26 Thousand USD | -311.06% |
| 2023 Q2 | -166.04 Thousand USD | -24.56% |
| 2023 Q1 | -133.31 Thousand USD | -183.77% |
| 2022 Q1 | 220.37 Thousand USD | -54.61% |
| 2022 FY | - USD | -85.31% |
| 2022 Q2 | 91.99 Thousand USD | -58.25% |
| 2022 Q3 | -119.07 Thousand USD | -229.44% |
| 2022 Q4 | -46.97 Thousand USD | 60.55% |
| 2021 Q4 | 485.49 Thousand USD | 180.11% |
| 2021 Q3 | 173.32 Thousand USD | 1.49% |
| 2021 Q2 | 170.78 Thousand USD | 12.75% |
| 2021 Q1 | 151.47 Thousand USD | -54.17% |
| 2021 FY | - USD | 37.72% |
| 2020 Q3 | 217.62 Thousand USD | 955.34% |
| 2020 Q1 | 166.71 Thousand USD | 196.83% |
| 2020 FY | - USD | 479.01% |
| 2020 Q2 | -25.44 Thousand USD | -115.26% |
| 2020 Q4 | 330.52 Thousand USD | 51.88% |
| 2019 Q2 | -18.56 Thousand USD | -430.18% |
| 2019 Q3 | 4232.00 USD | 122.79% |
| 2019 Q4 | -172.17 Thousand USD | -4168.45% |
| 2019 FY | - USD | 22.38% |
| 2019 Q1 | -3502.00 USD | 96.01% |
| 2018 FY | - USD | 38.87% |
| 2018 Q4 | -87.71 Thousand USD | -108.27% |
| 2018 Q3 | -42.11 Thousand USD | 80.57% |
| 2018 Q2 | -216.74 Thousand USD | -319.56% |
| 2018 Q1 | 98.72 Thousand USD | 120.92% |
| 2017 Q1 | -2388.00 USD | 99.16% |
| 2017 FY | - USD | -63.3% |
| 2017 Q4 | -471.95 Thousand USD | -899.15% |
| 2017 Q3 | 59.05 Thousand USD | 350.85% |
| 2017 Q2 | 13.09 Thousand USD | 648.53% |
| 2016 FY | - USD | 42.89% |
| 2016 Q1 | 40.48 Thousand USD | 111.29% |
| 2016 Q4 | -283.94 Thousand USD | -469.43% |
| 2016 Q3 | -49.86 Thousand USD | -160.25% |
| 2016 Q2 | 82.76 Thousand USD | 104.42% |
| 2015 Q1 | 6653.00 USD | 100.9% |
| 2015 FY | - USD | 36.42% |
| 2015 Q4 | -358.66 Thousand USD | -819.02% |
| 2015 Q3 | -39.02 Thousand USD | 2.88% |
| 2015 Q2 | -40.18 Thousand USD | -704.0% |
| 2014 Q3 | -23.35 Thousand USD | -211.22% |
| 2014 FY | - USD | -6.65% |
| 2014 Q4 | -743.17 Thousand USD | -3082.74% |
| 2014 Q2 | 20.99 Thousand USD | -68.8% |
| 2014 Q1 | 67.29 Thousand USD | 113.16% |
| 2013 Q2 | -45.88 Thousand USD | 39.15% |
| 2013 Q4 | -511.41 Thousand USD | -15772.63% |
| 2013 Q1 | -75.4 Thousand USD | -371.85% |
| 2013 Q3 | -3222.00 USD | 92.98% |
| 2013 FY | - USD | -410.04% |
| 2012 Q3 | -46.86 Thousand USD | -504.1% |
| 2012 Q4 | -15.98 Thousand USD | 65.9% |
| 2012 FY | - USD | 53.46% |
| 2012 Q1 | -54.08 Thousand USD | 73.2% |
| 2012 Q2 | -7757.00 USD | 85.66% |
| 2011 Q2 | -174.12 Thousand USD | -817.76% |
| 2011 Q4 | -201.82 Thousand USD | -767.69% |
| 2011 Q3 | 30.22 Thousand USD | 117.36% |
| 2011 Q1 | 24.25 Thousand USD | 13.58% |
| 2011 FY | - USD | -205.1% |
| 2010 Q1 | 98.22 Thousand USD | 113.71% |
| 2010 FY | - USD | 113.28% |
| 2010 Q4 | 21.35 Thousand USD | -74.24% |
| 2010 Q3 | 82.91 Thousand USD | 58.31% |
| 2010 Q2 | 52.37 Thousand USD | -46.68% |
| 2009 Q3 | -679.08 Thousand USD | -1797.04% |
| 2009 FY | - USD | -263.22% |
| 2009 Q1 | -135.65 Thousand USD | 55.1% |
| 2009 Q2 | 40.01 Thousand USD | 129.5% |
| 2009 Q4 | -716.67 Thousand USD | -5.54% |
| 2008 Q3 | 606.21 Thousand USD | 3.01% |
| 2008 Q2 | 588.52 Thousand USD | 100.87% |
| 2008 Q4 | -302.13 Thousand USD | -149.84% |
| 2008 Q1 | 292.98 Thousand USD | 108.98% |
| 2008 FY | - USD | 126.93% |
| 2007 Q4 | -3.26 Million USD | -837.43% |
| 2007 FY | - USD | -445.37% |
| 2007 Q1 | -303.72 Thousand USD | -99.3% |
| 2007 Q2 | -435.26 Thousand USD | -43.31% |
| 2007 Q3 | -348.07 Thousand USD | 20.03% |
| 2006 Q3 | -734.49 Thousand USD | -347.39% |
| 2006 Q1 | 28.89 Thousand USD | 82.29% |
| 2006 Q4 | -152.39 Thousand USD | 79.25% |
| 2006 FY | - USD | -1193.59% |
| 2006 Q2 | -164.17 Thousand USD | -668.27% |
| 2005 Q4 | 15.84 Thousand USD | -72.68% |
| 2005 FY | - USD | -42.75% |
| 2005 Q3 | 57.99 Thousand USD | 1488.58% |
| 2005 Q1 | -4274.00 USD | 0.0% |
| 2005 Q2 | 3651.00 USD | 185.42% |
| 2004 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 57.904% |
| Ansell Limited | 209.86 Million USD | 100.193% |
| Ansell Limited | 206.3 Million USD | 100.197% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | 42.83 Million USD | 100.947% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 75.028% |
| Psykey, Inc. | -1.29 Million USD | 68.673% |
| ConvaTec Group Plc | 455.5 Million USD | 100.089% |
| ConvaTec Group Plc | 455.5 Million USD | 100.089% |
| Encision Inc. | -544.19 Thousand USD | 25.434% |
| Golden Valley Development, Inc | -141.81 Thousand USD | -186.146% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | -269.129% |
| Innovative MedTech Inc. | -7.67 Million USD | 94.712% |
| LifePoint, Inc. | -14.2 Million USD | 97.143% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 93.441% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | -24.857% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | -88.532% |
| SmileDirectClub, Inc. | -186.13 Million USD | 99.782% |
| Sector 10, Inc. | - USD | Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 100.091% |
| SheerVision, Inc. | -110.53 Thousand USD | -267.122% |
| United Health Products, Inc. | -2.5 Million USD | 83.783% |
| Vasamed, Inc. | -4.57 Million USD | 91.129% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 82.051% |
| Yubo International Biotech Limited | -1.17 Million USD | 65.544% |